Trials / Completed
CompletedNCT04358432
A Study of PCSK9 Inhibitor AK102 in Patients With Hypercholesterolemia
A Double-blind, Randomized, Placebo-controlled, Multicenter Phase II Study of AK102 in the Treatment of Hypercholesterolemia Patients at Very High or High Risk of Cardiovascular Disease
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 262 (actual)
- Sponsor
- Akeso · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a double-blind, randomized, placebo-controlled, multicenter study to evaluate the safety and efficacy of AK102 in patients with Hypercholesterolemia Patients at Very High or High Risk of Cardiovascular Disease . The primary objective of this study is to evaluate the efficacy of AK102 in patients with Hypercholesterolemia Patients at Very High or High Risk of Cardiovascular Disease .
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AK102 | Administered by subcutaneous injection |
| DRUG | Placebos | Administered by subcutaneous injection |
| DRUG | Statins and/or Ezetimibe | Lipid-lowering therapies |
Timeline
- Start date
- 2020-05-13
- Primary completion
- 2021-02-25
- Completion
- 2021-02-25
- First posted
- 2020-04-24
- Last updated
- 2023-03-02
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04358432. Inclusion in this directory is not an endorsement.